Bristol Myers Squibb unveils five year data reinforcing long term efficacy and safety of Camzyos in symptomatic obstructive hypertrophic cardiomyopathy at ESC Congress 2026

New single arm, open label results add to the growing body of evidence supporting consistent clinical benefit and safety with Camzyos, extending the longest running clinical development program for a cardiac myosin inhibitor in symptomatic oHCM

Additional presentations at ESC Congress build on the established effectiveness and safety profile of Camzyos observed in real world settings

Bristol Myers Squibb presented findings from the EXPLORER-LTE cohort of the MAVA-LTE study in a late breaker session at the European Society of Cardiology Congress 2026 in Munich, Germany. EXPLORER-LTE represents the largest and longest evaluation to date of patients with symptomatic obstructive hypertrophic cardiomyopathy treated with Camzyos, the most extensively studied cardiac myosin inhibitor and a standard of care for patients in New York Heart Association class II to III. The data reinforce that Camzyos’ effects remain sustained for up to five years with continuous, consistent treatment. Additional presentations from COLLIGO-HCM, a global retrospective real world data study, further strengthen the existing real world evidence base for Camzyos, helping guide treatment decisions for people living with the condition.

Anjali T. Owens, MD, medical director of the Center for Inherited Cardiac Disease and associate professor of medicine at the University of Pennsylvania’s Perelman School of Medicine, said the five year EXPLORER-LTE data reflect the sustained, clinically meaningful benefits of Camzyos for patients living with symptomatic oHCM. She said that for a chronic, progressive condition requiring ongoing treatment and monitoring, long term evidence plays an essential role in helping clinicians understand how a therapy may benefit patients over time.

EXPLORER-LTE is a single arm, open label, dose blinded extension of the Phase 3 EXPLORER-HCM study, designed to evaluate the long term safety and efficacy of Camzyos. In total, 231 patients who completed EXPLORER-HCM went on to enroll in the extension study. A substantial share of patients experienced sustained, clinically meaningful reductions in left ventricular outflow tract obstruction, improved by at least one NYHA class, and showed notable gains in echocardiographic measures and biomarkers. No new safety signals emerged beyond those already observed in the original EXPLORER-HCM study.

At week 252, treatment with Camzyos produced mean changes from baseline at the start of the extension study of -38.7 mm Hg in resting LVOT gradient and -55.6 mm Hg in Valsalva LVOT gradient. Nearly all patients, 97.4 percent, achieved a Valsalva LVOT gradient of 30 mm Hg or below, the threshold used to define obstruction in patients with oHCM. Improvement of at least one NYHA class was seen in 69.6 percent of patients, and 59.2 percent were asymptomatic. Mean left ventricular ejection fraction declined by 10.2 percent but remained within the normal range. Safety findings were consistent with those previously reported in the primary EXPLORER-HCM study.

Additional data presented at ESC Congress further support Camzyos and deepen understanding of the broader impact of oHCM. Two presentations from COLLIGO-HCM added to the well established real world evidence supporting Camzyos in clinical practice, showing a real world effectiveness and safety profile that remained consistent across patients, with symptom improvement and reduced LVOT obstruction. A complementary analysis from a real world observational registry study in Germany reinforced the effectiveness of Camzyos across different geographic populations, with patients achieving NYHA class reductions consistent with previously reported real world data. These findings build on the existing evidence base for Camzyos and confirm that the improvements observed in clinical trials are also being achieved in real world practice. A separate analysis of a healthcare resource utilization study in Sweden added to the understanding of the broader burden of hypertrophic cardiomyopathy and obstructive hypertrophic cardiomyopathy specifically, underscoring the heightened impact of the obstructive form and the importance of accurate diagnosis and consistent care for those living with it.

Cristian Massacesi, MD, executive vice president, chief medical officer, and head of development at Bristol Myers Squibb, said long term and real world evidence gives people living with symptomatic oHCM greater confidence in treatment decisions and a clearer picture of what sustained therapy can mean over time. He said the data presented at ESC Congress, part of the company’s broader commitment to advancing cardiovascular research, add to the understanding and confidence in Camzyos and its role in helping patients manage oHCM, a serious condition that affects daily life for many of those living with it.

---

---

Related Topics and Keywords

Bristol-Myers Squibb, CAMZYOS® (mavacamten), ESC Congress 2026, obstructive hypertrophic cardiomyopathy